1740 related articles for article (PubMed ID: 24552317)
21. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.
Narayana A; Gruber D; Kunnakkat S; Golfinos JG; Parker E; Raza S; Zagzag D; Eagan P; Gruber ML
J Neurosurg; 2012 Feb; 116(2):341-5. PubMed ID: 22035272
[TBL] [Abstract][Full Text] [Related]
22. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
[TBL] [Abstract][Full Text] [Related]
23. Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab.
Zhong J; Ali AN; Voloschin AD; Liu Y; Curran WJ; Crocker IR; Shu HK
Cancer; 2015 May; 121(9):1456-62. PubMed ID: 25557543
[TBL] [Abstract][Full Text] [Related]
24. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
Kovic B; Xie F
J Clin Oncol; 2015 Jul; 33(20):2296-302. PubMed ID: 26014296
[TBL] [Abstract][Full Text] [Related]
25. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.
Perry JR; Laperriere N; O'Callaghan CJ; Brandes AA; Menten J; Phillips C; Fay M; Nishikawa R; Cairncross JG; Roa W; Osoba D; Rossiter JP; Sahgal A; Hirte H; Laigle-Donadey F; Franceschi E; Chinot O; Golfinopoulos V; Fariselli L; Wick A; Feuvret L; Back M; Tills M; Winch C; Baumert BG; Wick W; Ding K; Mason WP;
N Engl J Med; 2017 Mar; 376(11):1027-1037. PubMed ID: 28296618
[TBL] [Abstract][Full Text] [Related]
26. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
Brandes AA; Gil-Gil M; Saran F; Carpentier AF; Nowak AK; Mason W; Zagonel V; Dubois F; Finocchiaro G; Fountzilas G; Cernea DM; Chinot O; Anghel R; Ghiringhelli F; Beauchesne P; Lombardi G; Franceschi E; Makrutzki M; Mpofu C; Urban HJ; Pichler J
Oncologist; 2019 Apr; 24(4):521-528. PubMed ID: 30266892
[TBL] [Abstract][Full Text] [Related]
27. A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.
Clarke JL; Molinaro AM; Phillips JJ; Butowski NA; Chang SM; Perry A; Costello JF; DeSilva AA; Rabbitt JE; Prados MD
Neuro Oncol; 2014 Jul; 16(7):984-90. PubMed ID: 24637230
[TBL] [Abstract][Full Text] [Related]
28. Bevacizumab as secondline treatment of glioblastoma - worth the effort?
Rovere RK
Klin Onkol; 2014; 27(3):219-20. PubMed ID: 24918282
[TBL] [Abstract][Full Text] [Related]
29. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability.
Lai A; Filka E; McGibbon B; Nghiemphu PL; Graham C; Yong WH; Mischel P; Liau LM; Bergsneider M; Pope W; Selch M; Cloughesy T
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1372-80. PubMed ID: 18355978
[TBL] [Abstract][Full Text] [Related]
30. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
31. Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme.
van Linde ME; Verhoeff JJ; Richel DJ; van Furth WR; Reijneveld JC; Verheul HM; Stalpers LJ
Oncologist; 2015 Feb; 20(2):107-8. PubMed ID: 25582142
[TBL] [Abstract][Full Text] [Related]
32. Patterns of care and survival of glioblastoma patients: a comparative study between 2004 and 2008 in Lyon, France.
Badaoui N; Meyronet D; Cartalat-Carel S; Guyotat J; Jouanneau E; d'Hombres A; Sunyach MP; Jouvet A; Louis-Tisserand G; Archinet A; Frappaz D; Bauchet L; Honnorat J; Ducray F
Rev Neurol (Paris); 2014 Mar; 170(3):222-7. PubMed ID: 24582303
[TBL] [Abstract][Full Text] [Related]
33. Potential novel role of bevacizumab in glioblastoma and cervical cancer.
Goey AK; Figg WD
Cancer Biol Ther; 2014 Oct; 15(10):1296-8. PubMed ID: 25046485
[TBL] [Abstract][Full Text] [Related]
34. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.
Hainsworth JD; Ervin T; Friedman E; Priego V; Murphy PB; Clark BL; Lamar RE
Cancer; 2010 Aug; 116(15):3663-9. PubMed ID: 20564147
[TBL] [Abstract][Full Text] [Related]
35. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
Hasselbalch B; Lassen U; Hansen S; Holmberg M; Sørensen M; Kosteljanetz M; Broholm H; Stockhausen MT; Poulsen HS
Neuro Oncol; 2010 May; 12(5):508-16. PubMed ID: 20406901
[TBL] [Abstract][Full Text] [Related]
36. Lomustine and Bevacizumab in Progressive Glioblastoma.
Wick W; Gorlia T; Bendszus M; Taphoorn M; Sahm F; Harting I; Brandes AA; Taal W; Domont J; Idbaih A; Campone M; Clement PM; Stupp R; Fabbro M; Le Rhun E; Dubois F; Weller M; von Deimling A; Golfinopoulos V; Bromberg JC; Platten M; Klein M; van den Bent MJ
N Engl J Med; 2017 Nov; 377(20):1954-1963. PubMed ID: 29141164
[TBL] [Abstract][Full Text] [Related]
37. Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.
Chinot OL; Nishikawa R; Mason W; Henriksson R; Saran F; Cloughesy T; Garcia J; Revil C; Abrey L; Wick W
Neuro Oncol; 2016 Sep; 18(9):1313-8. PubMed ID: 27006178
[TBL] [Abstract][Full Text] [Related]
38. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
Reardon DA; Brandes AA; Omuro A; Mulholland P; Lim M; Wick A; Baehring J; Ahluwalia MS; Roth P; Bähr O; Phuphanich S; Sepulveda JM; De Souza P; Sahebjam S; Carleton M; Tatsuoka K; Taitt C; Zwirtes R; Sampson J; Weller M
JAMA Oncol; 2020 Jul; 6(7):1003-1010. PubMed ID: 32437507
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma.
Omuro A; Beal K; Gutin P; Karimi S; Correa DD; Kaley TJ; DeAngelis LM; Chan TA; Gavrilovic IT; Nolan C; Hormigo A; Lassman AB; Mellinghoff I; Grommes C; Reiner AS; Panageas KS; Baser RE; Tabar V; Pentsova E; Sanchez J; Barradas-Panchal R; Zhang J; Faivre G; Brennan CW; Abrey LE; Huse JT
Clin Cancer Res; 2014 Oct; 20(19):5023-31. PubMed ID: 25107913
[TBL] [Abstract][Full Text] [Related]
40. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
Vredenburgh JJ; Desjardins A; Kirkpatrick JP; Reardon DA; Peters KB; Herndon JE; Marcello J; Bailey L; Threatt S; Sampson J; Friedman A; Friedman HS
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):58-66. PubMed ID: 21036490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
